Post-fracture thromboprophylaxis: is it time for a change?

Bartoli, Arianna; Mascolo, Ruggiero; Tosti, Giulia; Luciano, F.; Caturano, Alfredo

doi:10.1007/s11739-023-03369-7

Intern Emerg Med

2023

DOI: 10.1007/s11739-023-03369-7

|View full text |Cite

Post-fracture thromboprophylaxis: is it time for a change?

Arianna Bartoli¹,

Ruggiero Mascolo²,

Giulia Tosti³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis

Caturano,

Brunelli,

Spiezia

et al. 2023

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), stands as the third leading cause of vascular-related mortality on a global scale. Anticoagulation prophylaxis undeniably ensures a significant reduction in the risk of DVT, while simultaneously exposing individuals to an elevated likelihood of experiencing both major and minor bleeding events. Betrixaban is a novel oral anticoagulant, a direct factor Xa inhibitor, approved by the Food and Drug Administration (FDA) but not by the European Medicines Agency (EMA) for VTE thromboprophylaxis. The current necessity revolves around the acquisition of a substantial volume of data to dispel the uncertainties associated with this drug due to its non-approval by the EMA. Consequently, we eagerly await the results of post-marketing pharmacovigilance efforts to provide further insights into the performance of betrixaban within the broader population.

show abstract

An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis

Caturano,

Brunelli,

Spiezia

et al. 2023

Journal of Cardiovascular Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Post-fracture thromboprophylaxis: is it time for a change?

Cited by 1 publication

References 5 publications

An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis

An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis

Contact Info

Product

Resources

About